Shares in Intersect ENT (NSDQ:XENT) fell slightly yesterday after the drug-device maker met expectations on Wall Street with its 1st quarter results.
The Menlo Park, Calif.-based company posted a loss of -$6.8 million, or -23¢ per share, on sales of $20.5 million for the 3 months ended March 31, for bottom-line growth of 20% on sales growth of 22.8% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT beats Q1 earnings, rev forecast appeared first on MassDevice.